MYGN Myriad Genetics, Inc.

NASDAQ
$5.53

Myriad Genetics, Inc. (MYGN) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.33 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.7% since its last earnings release on November 4, 2026.

Myriad Genetics Beat Consensus Estimates, Narrows Guidance
Wednesday, November 4, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.33)
Rev est $192.97M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.83

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Myriad Genetics, Inc.

Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Sector

Healthcare

Industry

Medical Labs & Research

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.